Galapagos NV, operating as Lakefront Biotherapeutics, announced that its Board of Directors approved the Subscription Right Plan November 2026 on November 10, 2026. Under this plan, 150,000 subscription rights were created to compensate current and potential future employees within the framework of the authorized capital. Each subscription right entitles the holder to subscribe for one new Lakefront share.
The company’s total share capital currently stands at €356,444,938.61, with 65,897,071 securities conferring voting rights, which equals the total number of shares outstanding. All voting securities, voting rights, and shares belong to a single category.
Voting rights attached to the 1,985,157 repurchased shares held by the company are currently suspended. Beyond the new plan, outstanding rights to subscribe for not-yet-issued voting securities include 14,197,983 subscription rights under other existing employee subscription right plans, as well as one subscription right granted to Gilead Therapeutics allowing it to subscribe for a maximum number of shares sufficient to bring the combined shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares.
Also Read
- Askari General Insurance Releases Nine-Month Financial Results for the Period Ended September 30, 2026
- World’s Best School Award Goes to London’s Swiss Cottage Centre, Where “Every Child Belongs”
- EDF snaps up 1.3m more customers after Utilita takeover
- Anthropic’s $81 Billion IPO Among Largest Listings


